TrialAssure launches TrialResults.com
TrialAssure launches TrialResults.com TrialAssure, a global software company focused on developing clinical trial transparency tools, has announced the launch of TrialResults.com, a new portal for sponsors to publicly share plain language, or lay, summaries with clinical trial participants. This portal allows trial participants to access the plain language summaries in any region of the world and in their native language.
In place of mailing paper copies of the plain language summaries to participants, sponsors can upload the summary onto the portal.
Using TrialResults.com takes just three steps:
- Clinical research organizations and sponsors upload completed plain language summaries onto the portal
- Users enter the unique trial identifier that has been provided to them into the search bar
- The relevant plain language summary appears
Currently, only 2 percent of clinical trial sponsors have issued plain language summaries to participants in the past few years, as recently reported by Applied Clinical Trials.
“TrialResults.com comes at a crucial time in the pharmaceutical industry when the requirement for posting lay summaries is looming,” said Alan Nicolle, Director, Business Development & Business Alliance Partnerships at TrialAssure in London.
Learn more at www.trialresults.com
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
